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Abstract
Objective: This study aims to systematically evaluate available evidence regarding direct medical costs of treating
cardiovascular (CV) events in Germany after 2003 on an individual patient basis and from a payer perspective. The
CV events of interest were myocardial infarction (MI), unstable angina, heart failure (HF), stroke, and peripheral artery
disease (PAD).
Method: A systematic literature search was performed in the following databases according to Preferred Reporting
Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines - Medline, Embase, Centre for Reviews
and Dissemination, TIBORDER, and German dissertation database from January 2003 to October 2013. Both
observational studies and randomized clinical trials were considered for the review. All values stated in € are inflation
adjusted to 2014 € unless stated otherwise.
Result: This review included 13 articles. For newly occurred MI patients, the average hospitalization costs during the
acute phase were reported to be between € 6790 and € 8918 per admission. In the first year after a MI event, direct
medical costs were € 13,838–14,792 per patient. Direct medical costs of chronic HF patients were found to be between
€ 3417 and 5576 per patient per year. Treatment costs increase with disease progression. The average treatment costs
for hospitalized PAD in the acute phase were reported to be € 4963 per admission, € 2535 per patient during month
1–6 after the initial hospitalization, € 1601 in month 7–12, and € 1390 in month 13–18. For stroke of all types, total
direct medical costs in the 1st year after an event were reported to be € 13,273 per patient. Total direct medical costs
during the 1st year after an ischemic stroke event were € 17,399–21,954 per patient, € 6260 in month 13–18, and
€ 6496 per year in the subsequent 4 years.
Conclusion: MI, unstable angina, HF, stroke and PAD have a high financial impact on the German health care system.
Treatment costs of these diseases are mostly incurred during the acute phase of events and tend to decrease over
time. Hospitalization and rehabilitation costs were two major cost drivers. Medication costs was one of the smallest
cost component reported.
Review
Cardiovascular (CV) events are mainly disorders of heart
and blood vessels, including coronary heart disease (CHD),
cerebrovascular disease (mainly stroke), and peripheral
artery disease (PAD). In 2012, CHD is the leading cause of
death worldwide, with an estimated 7.4 million people died
from it followed by 6.7 million died from stroke. In
Germany in 2012, CHD was number one cause with a pro-
portion of 40,2 % on overall death [1, 2].
Acute CHD, stroke, and PAD often require intensive
treatments, such as coronary artery bypass grafting
(CABG), percutaneous coronary intervention (PCI) and/or
fibrinolysis. Often patients experiencing these disorders
also need long-term treatment and care, as well as manage-
ment after the acute stage. All these treatments and proce-
dures lead to a tremendous economic burden to the
patients, third party payers, and the society as a whole.
In Germany, CV event is highly incident and is one of
the most expensive diseases. DEGS1 studies (Results of
the German Health Interview and Examination Survey for
Adults) from 2013 discovered a lifetime prevalence of
overall CHD in Germany of 9.3 % among women and
men aged 40 to 79 years [3]. According to the 2008
Federal Health Report published by the Federal Statistical
Office of Germany, the costs caused by CV events
amounted to € 35.5,000,000,000, which was 1/6 of the
total expenditure of healthcare provision in Germany in
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that year [4]. Moreover, CHD, angina pectoris, stroke, and
MI are among the 20 leading causes for hospitalization
[5]. 40 % of people in Germany die due to cardiovascular
diseases. Among all CV events, cerebrovascular dis-
eases such as stroke accounted for € 7.8,000,000,000,
ischemic heart disease such as cardiac infarction for
€ 7,000,000,000, and heart failure for € 2.7,000,000,000 in
2008 [6].
However, there is a gap in publications with respect to
the individual treatment costs of CV events, especially
after the implementation of German diagnostic-related
groups (G-DRG) in hospitals in 2003 [7], which gave
healthcare providers incentives to shorten the length of
stay and be more cost-conscious [8].
This systematic literature review aims to provide an
overview of the costs of treating individual CV event pa-
tients after 2003 from a third-party payer perspective. The
CV events of interest were myocardial infarction (MI),
unstable angina, heart failure (HF), stroke, and PAD.
Methods
Identification of studies
A systematic literature search was conducted to identify
all available publications about individual-level direct
medical costs of the CV events of interest in Germany
after the G-DRG reform. We adopted the perspective of
healthcare providers and German social third party
payers, including statutory health insurance (SHI) and
statutory nursing insurance (SNI) for cost studies. The
scope of the costs was restricted to direct medical costs
per affected patient, including hospitalization costs
(based on the G-DRG system), outpatient costs (based
on the points assigned to the particular treatment pub-
lished in the German tariff list), medication costs (based
on the reimbursement price of German SHI, rather than
the price set by manufacturers), and rehabilitation and
ambulance/paramedic costs (based on the costs reim-
bursed by the German SHI or SNI).
The review was conducted according to the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines [9].
Publications between January 1st 2003 and October 1st
2013 in English or German were searched in the following
databases: Medline, Embase, Centre for Reviews and Dis-
semination (CRD) database, TIBORDER database, and
German dissertation database.
Published papers, conference abstracts, and disserta-
tions were all included in this review. Search terms are
presented in Table 1.
Observational, epidemiological studies and randomized
clinical trials (RCTs) with individual cost information were
included. For RCT publications, the RCT was included in
the review if there was original information about costs.
References of the RCT studies were reviewed by hand for
sources of original cost data.
Exclusion criteria were: setting was not Germany; not
SHI perspective or healthcare provider perspective
adopted; not including the CV events of interest; costs
data before 2003; costs on individual level not available
or not calculable; costs reported originated from other
studies (in this case the cited study was hand-searched
and reviewed); and costs evaluation using health eco-
nomic models or truncated approaches (no direct data).
One researcher conducted the search. If there was
doubt regarding the inclusion/exclusion of an article,
another independent researcher was consulted.
All values stated in € are inflation-adjusted to 2014 €
unless stated otherwise.
Data extraction and analysis
Relevant data was extracted in a Microsoft Excel file.
The extracted parameters included study identification,
study characteristics (i.e. objective, setting, perspective),
type of CV events, intervention (i.e. % of each cardiovas-
cular treatments, such as drug treatment, PCI, CABG,
etc.), participants characteristics (i.e. gender, age, comor-
bidities), direct medical costs (including cost in acute
phase, costs within the first year after the event and
follow-up costs from the second year onwards), conclu-
sion and limitations of the study.
Results
The search resulted in 400 hits. The reviewer removed
50 duplicated papers, leaving 350 papers for title and
abstract-based selection. There were 64 articles/abstracts
(including 4 additional papers based on hand search
from citations of relevant papers) included for full-text
screening, among which 51 articles/abstracts were excluded
based on the pre-defined exclusion criteria: 9 studies were
excluded because the reported CV event (e.g. atherothrom-
bosis) was not of interest for this study; 3 because German
costs were not separately reported; 24 because they failed
Table 1 Search terms for the systematic literature reviewa
Domain Search terms
Subject “cost” OR “costs” OR “expenditure” OR “economic”
OR “burden” OR “resource”
Setting “German” OR “Germany” [full text]
Cardiovascular
events
“myocardial infarction” OR “myocardial infarction”
[MeSH]
“unstable angina” OR “angina, unstable” [MeSH]
“heart failure” OR “heart failure” [MeSH]
“peripheral vascular disease” OR “peripheral vascular
event” OR “peripheral artery disease” OR “peripheral
vascular diseases” [MeSH]
“stroke” OR “stroke” [MeSH]
aThe terms are searched in title/abstract if there is no additional explanation
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to report individual costs, instead they reported incremental
costs of interventions compared to base treatments; 8 due
to lack of individual cost data; 4 studies reported costs
based on data before 2003; 3 studies reported costs using a
model or using truncated approach based on indirect data.
Ultimately, there were 13 studies included in this review,
with several studies addressing multiple CV events.
The selection procedure was recorded following the
PRISMA flowchart (Fig. 1).
Myocardial infarction
Seven papers and one abstract reported direct medical
cost of individual MI patients in Germany [10–17].
In the literature, methods used to investigate costs of
MI include a claims data analysis, a hospital database
analysis, medical chart review, and calculations of costs
based on healthcare resource utilization from expert
panels (or literature review and expert interview) and
SHI price. Although there was no clear definition in the
included articles regarding acute and long-term treat-
ment of MI, treatment costs can be roughly categorized
into costs during acute phase (or hospitalization costs),
costs within 1 year after event, and long-term costs after
event (normally from the 2nd year onwards).
For newly occurred acute myocardial infarction (AMI)
patients, the average hospitalization costs during acute
phase ranged from € 3622 to 8918/patient [11, 13, 15–17].
During the first year after an AMI event, direct med-
ical costs of treating AMI patients were reported to be
from € 13,838 to 14,792/patient [10, 17]. Total costs
spent on male patients were about 21 % higher than
those for females (p ≤0.0001) [13]. Treatment costs
seemed to decrease over time during the 1st year after
an event. As estimated by Brüggenjürgen and Reinhold,
50–64 % of total costs in the first year were spent on
treatment within the acute phase, and 80–85 % of total
cost estimates were reached within 6 months after the
event [13, 17]. According to the study conducted by
Brüggenjürgen et al. hospitalization costs covered the
largest share (69 %) of total first-year costs, followed by
rehabilitation costs (14 %) and a relatively small propor-
tion on medication costs (8 %) [17].
Treatment costs were heavily influenced by treatment
strategies and the medical devices used. For example,
treatment costs of stent implementation depended on
the type of stent used: the use of bare-metal stent (BMS)
led to less resource use than drug-eluting stent (DES)
(€ 13,629 vs. 14,792, p <0.05), with more than 50 % of
costs occurring within 30 days after the implementation
Fig. 1 Flow chart of included studies
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[10]. Among patients who underwent PCI, in-hospital
treatment costs of contemporary antithrombotic strategies
(between € 3545 and 4755, roughly 1/3 of the total treat-
ment costs in the first year) were highly related to the
anticoagulant drug(s) used [12]. Inpatient cardiac rehabili-
tation for MI in the first year was also a significant cost
component of the total treatment costs, estimated to be €
2304/patient (around 14 % of the total 1st year costs) [14].
Direct treatment costs decreased to € 1163/patient
during month 13–18 after an AMI event [17].
Unstable angina
One study based on claims data was identified that
examined the direct medical costs of treating unstable
angina [18].
The published average costs for the inpatient treatment
per unstable angina patient (acute phase) were € 4442,
with inpatient cardiac rehabilitation being cheaper than
inpatient treatment only [18]. For hospital-admitted pa-
tients, the leading cost drivers were hospitalization costs
(€ 2414), followed by angiography costs (€ 829), diagnostic
costs (€ 683), and drug costs (€ 391, equal to 9 % of the
total costs) [18].
Heart failure
Two studies reported costs of treating HF from a SHI
perspective in Germany [19, 20]. Both were database
analyses.
Direct medical costs of CHF were calculated to be
between € 3417 and 5576/patient per year for patients of
all New York Heart Association (NYHA) levels [19, 20].
Biermann et al. found that the largest cost component
was related to hospitalizations (€ 2525, 74 %); while
costs of rehabilitation (€ 319, 9 %), medication (€ 315,
9 %) and outpatient contacts (€ 258, 8 %) were consider-
ably less important cost components [19]. Compared
with a cost of € 2683 per patient per year for NYHA
level I patient, there was a cost increase in NYHA II, III
and IV of 14, 48, and 71 %, respectively. About 76 % of the
cost increase resulted from augmented hospital (inpatient)
resource use [19].
Stroke
The review resulted in 5 papers regarding the direct med-
ical costs of treating stroke in Germany [16, 17, 21–23].
Different methods were applied in these studies, including
claims data analyses, calculations based on resource uti-
lization and SHI price, and retrospective cost-of-illness
study.
For stroke of all types, total direct medical costs in the
1st year after an event were reported to be € 13,273 per-
patient [22]. Male patients incurred approximately 10 %
more costs than females. About half of the costs were
incurred in the first 4 weeks after the event, 80 % of the
costs were reached in the first 6 months [16, 22].
Hospitalization costs accounted for the largest share
(75 %) of the total costs of treating stroke [22].
For ischemic stroke, total direct medical costs in the
1st year after the event were € 17,399–21,954 per patient
[17, 21, 23]. 29 % of the total costs in the 1st year
incurred in the acute phase, 66 % were reached within
6 months after the event [17]. 1st year treatment costs
for ischemic stroke patients varied due to the treatment
settings where they received rehabilitation treatments:
hospitalized patients had around € 3352 more costs per
patient per year compared to those treated in rehabilita-
tion centers [21]. For patients admitted to a hospital for
post-stroke rehabilitation, the leading components of 1st
year costs was hospitalization costs (€ 13,953), followed
by medicines (€ 1915) and outpatient care (€ 1066). For
patients who were admitted to a rehabilitation facility
for post-stroke rehabilitation, the leading components
were hospitalization costs (€ 8844), inpatient rehabilita-
tion care (€ 4788), medicines (€ 1691), and outpatient
care (€ 1317). For both groups, hospitalization (including
rehabilitation) is the main cost driver for rehabilitation
treatment of ischemic stroke patients [21]. Rehabilitation
accounted for the largest share (37 %) of costs in the
first year after an ischemic stroke event [23].
In month 13–18, costs of treating ischemic stroke
were € 6260 per patient [17]. During year 2 to 5 after
the event, direct medical costs decreased to € 6496 per
patient per year [23].
No cost information regarding hemorrhagic stroke and
transient ischemic attack was identified.
Peripheral artery disease
Only one paper was identified reporting direct medical
costs of treating PAD [17].
Using a Delphi panel to obtain healthcare resource
utilization and calculating costs based on reimbursed
price, Brüggenjürgen et al. reported that the average
treatment costs for hospitalized PAD in the acute phase
(hospitalization) were € 4963 per admission, € 2535 per
patient during month 1–6 after the initial hospitalization,
€ 1601 in month 7–12, and € 1390 in month 13–18 [17],
meaning that 54.5 % of the 1st year costs are consumed in
the acute phase and 82.4 % within the first 6 months.
The key results of all included studies are presented in
Table 2.
Conclusion
To summarize, MI, unstable angina, HF, stroke and PAD
are leading to high direct medical costs in Germany.
Treatment costs of MI, PAD and stroke mostly concen-
trate during the acute phase of the events and tend to
decrease over time. Figure 2 shows the results of the
studies that reported treatment costs in different time
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Table 2 Direct medical costs of several cardiovascular diseases in Germany (2003–2013) from a healthcare provider or SHI perspective
Study Disease Study design Sample size Gender
(% male)
Age
(mean ± SD years)
Unit of costs Costs in the acute
phase (actual






first 6 months (actual
costs; % of the costs
in the 1st year)b
Myocardial infarction and unstable angina
Stargardt 2013
[11]
MI Retrospective claim database
analysis






















2005 30 day (acute)
costs were 7761
for DES group and
6704 for BMS group
30 day (acute)
costs were 9030
for DES group and




MI Retrospective claim data
analysis
15,185 57.43 % 71.1 ± 12.6 2004/2005 € 5836; 50 % 6790 9897; 80 %
Tiemann 2008
[15]
AMI Retrospective study using
hospital administration data










MI Calculate costs based on
expert interview resource
utilization data/or published
data and German SHI price
n.a. n.a. Assume 70 %
over 60 years old






study in 19 hospitals of
different health care levels
407 67.1 % 65.9 (11.6) 2000–2002 € 3644 (SD 2195,
95 % CI: 3430–3858)
4442 (SD 2676,




MI Calculate costs based on
expert panel resource
utilization data and German
SHI price




CHF Retrospective panel study
using claims data
2,71 74.8 % 62.9 ± 13.6 2009 n.a. n.a. n.a.
Peters-Klimm 2012
[20]
CHF Retrospective medical chart
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PAD Calculate costs based on
expert panel resource
utilization data and German
SHI price













Table 2 Direct medical costs of several cardiovascular diseases in Germany (2003–2013) from a healthcare provider or SHI perspective (Continued)
Stroke
Abbas 2013 [21] Ischemic
Stroke










Lindig 2010 [22] Stroke Retrospective claim data
analysis
18,106 43.6 % 73.7 ± 12.6 years 2004/2005 € Around 50 % n.a. Around 80 %
Fuchs 2008 [16] Ischemic
stroke
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data and German SHI price
n.a. n.a. Assume 70 %
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n.a. 4792 ± 8249 5576 ± 9598 n.a. n.a. Total hospitalization: 3545
(8065), including HF 466 (1525),
other CV-related hospitalization
2596 (7469), and other causes of
hospitalization 483 (1894);
Total hospitalization: 4125
(9384), including HF 542 (1774),
other CV-related hospitalization
3020 (8690), and other causes
of hospitalization 562 (562);
53 % NYHA II, 45 %
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Note: “Costs” in this table is limited to direct medical costs from a SHI perspective in Germany. n.a. means not available. n.r. means not relevant
aInflation adjusted costs according to CPI: OECE statistics extracts, http://stats.oecd.org/Index.aspx?DataSetCode=MEI_CPI_WEIGHTS#, accessed on AUG 10 2015













frames. Hospitalization costs and rehabilitation costs are
two major cost drivers for all CV events of interest.
This suggests that it might be cost-saving to increase
investment into the prevention of these CV events in
order to avoid costly future hospitalization.
Discussion
This study is, to our knowledge, the first systematic litera-
ture review of direct medical costs of treating CV events
on individual patient’s level in Germany.
As what was found in this review, treatment costs of
CV events are high in developed countries. However, the
results are not comparable across studies from different
countries because of potential various treatment pat-
terns, reimbursement systems, different study years, etc.
For example, it was reported that the treatment costs of
AMI during 6 months post event were $ 2764–4953
(equal to 2014 € 2436–4365 [1]) in the US in 2005 [24].
In Sweden, the average costs of HF-related hospitaliza-
tions was SEK 72,613 (2014 € 8156) per patient per year;
in contrast, annual prescription costs were low: on aver-
age 3 % of total cost (SEK 3503, 2014 € 393 per patient)
[25]. Similar to that in Germany, in the US stroke seems
to be the most expensive CV event among those included
in this study. Based on 2.7,000 000 hospital admissions
with a diagnosis of stroke in the US, the average total
charge per admission were $ 46,518 (equal to 2014 €
35,2021) in 2009 [26].
In Germany, although treatment costs of CV events
are overall high, there was a substantial variance (around
€ 1000/patient per year) in the costs reported, especially
in stroke treatment (up to € 3000/patient per year).
Reported costs varied across studies due to the following
reasons: 1) different study design, 2) different patient
group, and 3) different treatment pattern.
Among the 13 studies identified in this review, re-
search methods adopted included claims data analyses,
which included relatively large sample sizes from multiple
healthcare providers [10, 11, 13, 21, 22]; retrospective
observational studies based on a few cardiovascular cen-
ters [12]; retrospective patient registry analyses, which
composed of various RCTs and cohorts [19, 23]; from
expert interviews or medical chart review [16, 17]; and
RCTs [14, 20].
As an example, Brüggenjürgen et al. [17] reported €
3780 and 4496 per patient more cost estimation for a
stroke patient during the end of acute phrase to 6 months
after event and 7–12 months after event, respectively,
compared to Lindig et al. [22] (see Fig. 2). As the Lindig
study is an observational one based on claims data, it
represented the real costs in the German practice.
The Brüggenjürgen study was based on experts’ opin-
ion regarding resource utilization and calculation using
published price; it might represent the “recommended”
treatment pattern and costs accordingly.
In general, results of RCTs are least representative for
the treatment costs of general CV patients in Germany
as they normally have strict recruitment procedures
based on patients’ baseline characteristics, health prob-
lems and medical history [27]. Results of the observational
studies, including only a few high-volume cardiovascular
centers, also need to be interpreted with caution as these
hospitals are likely to treat more severe patients (referred
to by secondary hospitals) leading to higher resource use
and costs per case. Moreover, as all of these studies
[12, 14, 20] evaluated the treatment costs of specific
treatment strategies, e.g. use of anticoagulants, out- and
inpatient rehabilitation, and a medical education program.
With these differences across studies, it is difficult to
ascertain representative data for direct medical costs in
Germany.
Fig. 2 Costs in treating MI, PAD, and stroke in the first year after CVE. Abbreviations: CVE, Cardiovascular Events, MI, Myocardial Infarction,
PAD, Peripheral Artery Disease, SHI, Statutory Health Insurance
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Due to different study objectives, researchers had vari-
ant inclusion and exclusion criteria (e.g. age, new disease
vs. recurrent disease, disease of different levels, etc.) for
cohorts. For example, Tiemann investigated the costs of
primary treatments of AMI patients to compare varia-
tions in hospitalization costs over 9 European countries,
including Germany [15]. In order to compare costs
across countries; selection of patients was strict in this
study. Only male patients between 50 and 60 years old
without relevant co-morbidities (e.g. diabetes, hyper-
tension, congestive heart failure, HIV infection) were
eligible. Furthermore, patients were only included in
the study if they came to an emergency department
within 2 h of symptom(s) onset. Furthermore, in
order to avoid the influence of very expensive proce-
dures on the overall results, patients who needed by-
pass surgery and PCI with complications were also
excluded from the analysis. Teaching hospitals have
not been included because they might have greater
resource intensity and higher costs per case. Due to
the extensive restrictions in patient selection, the re-
sults of this study can hardly be generalized to all
AMI patients in Germany.
Restrictions of patient groups were also implemented
in several other studies. For example, Reinhold et al.
and Kolominsky-Rabas et al. only included patients
who experienced their first-ever event (AMI and stroke,
respectively) and excluded recurrent events in their
studies respectively [13, 23]. How this restriction
influences direct medical costs per case is not clear.
In examining the costs of treating MI during acute
phase, Fuchs et al. [16] made an assumption of a
relatively old patient group for conducting the inter-
views, which makes their results less generalizable to
a wider (younger) patient population.
Different mixes of CHF patients were included in
the analyses with respect to NYHA level. The studies
of Biermann et al. [19] included patients of all four
NYHA categories, while the study of Peters-Klimms [20]
included 98 % of NYHA II or III patients. As it was
found by Biermann et al. [19] direct medical costs per
case increased with severity of HF, the results based on
patient groups of a certain NYHA level(s) might not be
generalized to patient of other NYHA levels.
Different treatment patterns might influence the
cost estimates reported in the studies. To compare
the costs and effectiveness of different stents (DES
and BMS), Bäumler et al. [10] only included patients
who underwent PCI treatment due to their first inci-
dence of AMI. As a result, the findings of this study
do not represent costs of the general AMI patient popu-
lation in Germany.
In order to compare resource utilization of ischemic
stroke patients who underwent rehabilitation in a hospital-
based unit or geriatric rehabilitation unit, Abbas et al.
[21] only included patients who underwent rehabilitation
treatment, whereas Lindig et al. [22] included patients
who were hospitalized due to stroke. Therefore, costs of
outpatient care were not included in these two studies.
Treatment costs are likely to be different across treat-
ment settings (i.e. hospital, rehabilitation center, outpatient
setting). For some diseases, such as AMI which is an acute
and life-threatening event and most patients are admitted
to a hospital, the results of studies including only hospital-
ized patients are likely to represent all patient groups. For
example, the restriction of the study conducted by Stargardt
et al. as inpatient only should not have significant influence
on the representativeness of the result of this study [11].
However, for some diseases which can be treated in all
settings, e.g. chronic heart failure, restrictions of treatment
setting might have influence on treatment pattern and
consequently treatment costs. For example, Biermann et al.
included treatment in both primary and hospital settings
[19]; while Peters-Klimm et al. only included patients
treated in primary care setting [20]. The results of these
two studies are therefore not comparable.
Despite the general awareness of the economic impact
of CV events in Germany, the number of observational
studies investigating the per-patient direct medical costs
is relatively small. It should be noted that no study was
identified for the costs of treating acute HF patients,
haemorrhagic stroke, and transient ischemic attack from
this literature review. There is a need for more research
in this area. This literature review is limited to published
studies through October 2013. Future literature reviews
should be able to include more recent information on
CV costs in Germany.
Endnote
1The midpoint exchange rate of Euro/USD was 0.7576
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